STAT Investigation Finds Little Evidence Behind Mitochondrial Replacement IVF Tourism

For biotech science and politics updates, sign up for STAT’s newsletter.

A zoology professor first sparked my interest in biology: my grandmother, whose dissertation, I believe, examined shrimp chromatophores. Remembering her this Día de los Muertos.

That memory offers a personal counterpoint to the clinical and commercial stories that follow. Biology can begin as close observation of an organism, then lead into questions about how cells work, what medicine can change, and how much confidence the evidence deserves. The distinction matters here: the two developments below involve different kinds of uncertainty, from how a regulator will assess a gene therapy application to what clinics can substantiate about an assisted-reproduction procedure.

FDA accepts UniQure’s Huntington’s application

UniQure said the FDA accepted its marketing application for AMT-130, a gene therapy for Huntington’s disease. The agency’s decision is due May 1, 2027. The company said the FDA is “tentatively planning” an advisory committee meeting to review the data. Read the company’s announcement.

Acceptance of a marketing application is a procedural milestone: it means the agency has accepted the submission for review, not that it has approved the treatment. The distinction can get lost in biotech announcements, where a filing update may be presented as a sign of momentum. For patients and families affected by Huntington’s disease, the more consequential questions are still ahead: what the submitted evidence shows, how the FDA interprets it, and whether the treatment’s potential benefits justify its risks.

Gene therapy aims to change how cells behave by delivering genetic material or otherwise altering gene activity. That broad description covers very different approaches, and the label alone doesn’t establish what a particular therapy does or how well it works. The source doesn’t describe AMT-130’s design or the clinical results in the application, so it would be premature to draw conclusions about its efficacy or safety from the filing notice.

The announced decision date gives the review a public timetable, while the word “tentatively” makes clear that the advisory committee meeting isn’t yet a settled event. Such committees can provide outside expertise and public discussion of difficult evidence questions, but the FDA makes the regulatory decision. If you’re following this application, the useful milestones will be the agency’s eventual review, any committee materials, and the evidence presented to support the company’s claims.

This is more significant than it looks as a process update, but it remains a process update. For a serious disease with major consequences for patients and families, urgency is understandable; it doesn’t remove the need to scrutinize what the data can and can’t establish.

Evidence lags behind IVF tourism pitch

Mitochondrial replacement, also called “three-parent IVF,” is being sold to older women as a way to turn back the biological clock and have a genetically related child. An eight-month STAT investigation found clinics and intermediaries promoting the treatment internationally, with customers spending tens of thousands of dollars despite scant evidence to support the pitch. The gap between the promise and the evidence is the central concern for anyone weighing this emerging medical tourism business.

The name “three-parent IVF” is attention-grabbing, but it can obscure what the procedure is meant to do. Mitochondrial replacement refers to techniques involving mitochondria, structures inside cells that have their own genetic material and help cells produce energy. In broad terms, the procedures seek to use one set of genetic material in combination with mitochondria from a donor. That description doesn’t mean a child inherits an equal share of DNA from three people, and the phrase shouldn’t be treated as a precise account of the biology.

The key claim in the reported marketing is more ambitious: that the treatment can help older women have a child genetically related to them. That raises a basic question for prospective patients: what evidence supports this use, for whom, and with what likelihood of success? The investigation’s finding of scant supporting evidence makes those questions especially pressing. A procedure can be technically possible without being proven to deliver the outcome a clinic advertises.

Medical tourism complicates the picture. Patients may encounter providers, intermediaries, and claims across borders, with different levels of transparency about evidence and follow-up. A clinic’s promotional language can be difficult to compare with independent clinical findings, especially for people facing a time-sensitive and emotionally charged decision. The sales pitch may sound clear; the evidence behind it may not.

And this is the part most people overlook: spending tens of thousands of dollars doesn’t itself tell a patient whether a treatment is supported by strong evidence. Price can signal how much a service costs, not how likely it is to work. People considering a procedure need clear information about what has been studied, what outcomes are known, and what remains uncertain. The source doesn’t provide enough detail to answer those questions for any particular clinic or patient.

Here’s the thing: fertility care already asks patients to make decisions amid uncertainty, and marketing can sharpen hope while smoothing over limits. That doesn’t establish that every provider makes the same claims or that every patient’s circumstances are alike. It does make the distance between a treatment’s advertised promise and the available evidence central to evaluating the business.

What the two stories have in common

The FDA application and the IVF tourism investigation concern very different settings, but both turn on how claims are tested. In the first, a company has submitted an application and the FDA’s review is pending. In the second, the investigation describes clinics and intermediaries selling a treatment despite scant evidence for the promise being made. One is a formal review process; the other raises questions about the information reaching customers.

That said, readers shouldn’t flatten the difference. A pending application doesn’t establish that a therapy works, and a lack of evidence for a particular marketing claim doesn’t prove that every use of a technique is ineffective. Precision matters, especially when the subject is medicine: what’s been submitted, what’s been demonstrated, and what’s being promised are separate questions.

For patients, families, and anyone reporting on biotechnology, the practical test is to look for the evidence behind each claim and to distinguish a milestone from an outcome. A filing accepted for review marks a stage in a regulatory process. A treatment promoted to consumers still needs support for the benefit being promised. In both cases, uncertainty is part of the story.

Still waiting for answers.

Continue to STAT+ to read the full story…